{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-007047","form_type":"8-K","ticker":null,"cik":"0001722964","company_name":"Y-mAbs Therapeutics, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.743165+00:00","generated_at":"2026-06-02T19:13:03.331636+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Y-mAbs reports Q1 2024: U.S. DANYELZA rev up 11% to $18.6M; net loss $0.15/share","bullets":["U.S. DANYELZA net revenue $18.6M (+11% YoY); worldwide $19.4M (-4% YoY on international stocking shipment in Q1 2023).","Net loss $6.6M ($0.15 per share), relatively flat vs Q1 2023 loss of $6.4M.","Cash $75.7M, cash burn $2.9M in Q1; FY2024 guidance reaffirmed: rev $95-100M, cash runway into 2027.","CFO Bo Kruse to resign upon successor appointment; search firm retained.","Adium launched DANYELZA in Brazil/Mexico in April; five new U.S. accounts added in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-007047","json":"https://secwatch.observer/filing/0001558370-24-007047.json","markdown":"https://secwatch.observer/filing/0001558370-24-007047.md","text":"https://secwatch.observer/filing/0001558370-24-007047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1722964/000155837024007047/0001558370-24-007047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1722964/000155837024007047/ymab-20240507x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T19:13:03.331636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"52c4f2f30909480c8e152f10b40abff1500b8646","claim":"Y-mAbs Therapeutics, Inc. updated its the quarter ended March 31, 2024 guidance (reaffirmed).","evidence_excerpt":"On May 7, 2024, Y-mAbs Therapeutics, Inc., announced its financial results for the quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1722964/000155837024007047/0001558370-24-007047-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}